Wells Fargo Upgrades Biogen to Overweight: Does the Alzheimer's Story Finally Have a Second Act?

Biogen received a bullish analyst call from Wells Fargo, with Mohit Bansal upgrading the stock to Overweight from Equal Weight and raising the price target to $250 from $200. The $50 increase in target implies materially improved expectations for the shares. The note is supportive for Biogen sentiment, but it is still analyst commentary rather than a company-reported operating update.

Analysis

Biogen received a bullish analyst call from Wells Fargo, with Mohit Bansal upgrading the stock to Overweight from Equal Weight and raising the price target to $250 from $200. The $50 increase in target implies materially improved expectations for the shares. The note is supportive for Biogen sentiment, but it is still analyst commentary rather than a company-reported operating update.